Trial Profile
A Multicentre, Open Label, Dose Escalation, Phase 1 Study in Patients With Unresectable or Metastatic Melanoma Receiving IMP321 (LAG-3Ig Fusion Protein-eftilagimod Alpha) as an Adjunctive Therapy to Anti-PD-1 Therapy With Pembrolizumab
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2019
Price :
$35
*
At a glance
- Drugs Eftilagimod alpha (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- Acronyms TACTI-mel
- Sponsors Immutep Limited
- 01 Dec 2019 Status changed from active, no longer recruiting to completed.
- 15 Oct 2019 Results published in an Immutep Limited Media Release
- 10 Oct 2019 According to an Immutep Limited media release, data from this trial will be presented at the World Immunotherapy Congress as part of Festival of Biologics 2019 on October 15-17, 2019.